ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Jul 20, 2021||ENDRA Life Sciences Announces Participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021|
|Jul 07, 2021||ENDRA Life Sciences Strengthens TAEUS(R) System Intellectual Property Protection with the Issuance of Three U.S. Patents|
|Jun 15, 2021||ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells|
|Jun 09, 2021||ENDRA Life Sciences Set to Join the Russell Microcap(R) Index|
|May 17, 2021||ENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update|
|Day Range||1.80 - 1.86|
|52 Week Range||0.65 - 3.10|
|Bid/Ask||1.82 / 1.86|
|Bid/Ask Size||600 X 600|
|Market Cap||76.68 million|
|Shares Outstanding||41.67 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|